{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:26:21Z","timestamp":1791901581508,"version":"4.3.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenia gravis (MG) is a chronic autoimmune disease characterized by muscle weakness and fatigue. It is caused by pathological autoantibodies against components expressed at neuromuscular junctions, such as acetylcholine receptor (AChR). Interleukin-6 (IL-6) has been suggested to play a role in the pathogenesis of MG, and IL-6 receptor (IL-6R) antibody treatment may provide a novel therapeutic option. In this study, we investigated the effects of IL-6R antibody treatment in an experimental autoimmune MG (EAMG) mouse model. We demonstrated that IL-6R antibody treatment improved muscle weakness, reduced IgG deposition at neuromuscular junctions, and the levels of AChR autoantibodies in serum. In addition, follicular helper T cells and Th17, plasma cells in lymph nodes were lower in IL-6R antibody treated mice. Our findings suggest that IL-6R blockade may be a novel and effective therapeutic strategy for the treatment of MG.<\/jats:p>","DOI":"10.3389\/fneur.2024.1356300","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:30:43Z","timestamp":1714537843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model"],"prefix":"10.3389","volume":"15","author":[{"given":"Shota","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshichika","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsue","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Tomizawa-Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Noguchi-Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor Ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"577634","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.4049\/jimmunol.1203032","article-title":"Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation","volume":"190","author":"Choi","year":"2013","journal-title":"J Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","article-title":"Characterization of anti-mouse interleukin-6 receptor antibody","volume":"84","author":"Okazaki","year":"2002","journal-title":"Immunol Lett"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e945","DOI":"10.1212\/NXI.0000000000000945","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molimm.2021.02.011","article-title":"Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis","volume":"133","author":"Chen","year":"2021","journal-title":"Mol Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"803101","DOI":"10.3389\/fimmu.2021.803101","article-title":"Gut microbiota as regulators of Th17\/Treg balance in patients with myasthenia gravis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00005-011-0158-6","article-title":"Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?","volume":"60","author":"Baggi","year":"2012","journal-title":"Arch Immunol Ther Exp"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"Chapter 15:Unit 15.8","DOI":"10.1002\/0471142735.im1508s21","article-title":"Experimental autoimmune myasthenia gravis in the mouse","author":"Wu","year":"2013","journal-title":"Curr Protoc Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","article-title":"Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis","volume":"180","author":"Mori","year":"2012","journal-title":"Am J Pathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12264-019-00344-1","article-title":"Enhancement of T follicular helper cell-mediated humoral immunity reponses during development of experimental autoimmune myasthenia gravis","volume":"35","author":"Cui","year":"2019","journal-title":"Neurosci Bull"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nri3447","article-title":"The good, the bad and the ugly - TFH cells in human health and disease","volume":"13","author":"Tangye","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/651503","article-title":"Th17 cells in autoimmune and infectious diseases","volume":"2014","author":"Zambrano-Zaragoza","year":"2014","journal-title":"Int J Inflam"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of myasthenia gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/sji.12057","article-title":"Expression of interleukin-22 in myasthenia gravis","volume":"78","author":"Zheng","year":"2013","journal-title":"Scand J Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaut.2015.09.005","article-title":"Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells","volume":"67","author":"Aricha","year":"2016","journal-title":"J Autoimmun"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.4049\/jimmunol.1002942","article-title":"Foxp3+ regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells","volume":"186","author":"Jang","year":"2011","journal-title":"J Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"eaaw7636","DOI":"10.1126\/sciimmunol.aaw7636","article-title":"Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-T cells","volume":"4","author":"Papillion","year":"2019","journal-title":"Sci Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"109141","DOI":"10.1016\/j.clim.2022.109141","article-title":"Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells","volume":"245","author":"Li","year":"2022","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1356300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:30:46Z","timestamp":1714537846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1356300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":35,"alternative-id":["10.3389\/fneur.2024.1356300"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1356300","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"article-number":"1356300"}}